1

1	Internal tremors and vibrations in long COVID: a cross-sectional study
2	
3	Tianna Zhou <sup>1</sup> ; Lindsay McAlpine <sup>2</sup> ; Teresa Michelsen <sup>3</sup> ; César Caraballo <sup>4</sup> ; Mitsuaki Sawano <sup>4</sup> ;
4	Bornali Bhattacharjee <sup>5,6</sup> ; Yuan Lu <sup>4,7</sup> ; Akiko Iwasaki <sup>5,6,8</sup> ; Harlan M. Krumholz <sup>4,6,7,9*</sup>
5	
6	1. Yale School of Medicine, New Haven, CT, USA
7	2. Department of Neurology, Yale School of Medicine, New Haven, CT, USA
8	3. Avocet Consulting LLC, Hoodsport, WA, USA
9	4. Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT,
10	USA
11	5. Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
12	6. Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA
13	7. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of
14	Medicine, New Haven, CT, USA
15	8. Howard Hughes Medical Institute, Chevy Chase, MD, USA
16	9. Department of Health Policy and Management, Yale School of Public Health, New Haven,
17	CT, USA
18	
19	* Corresponding author

20 Email: <u>harlan.krumholz@yale.edu</u> (HMK)

2

## 21 ABSTRACT

22 Background: Internal tremors and vibrations symptoms have been described as part of 23 neurologic disorders but have not been fully described as a part of long COVID. We compared 24 demographics, socioeconomic characteristics, pre-pandemic comorbidities, and new-onset 25 conditions between people with internal tremors and vibrations as part of their long COVID 26 symptoms and people with long COVID but without these symptoms. 27 Methods: A cross-sectional study, Listen to Immune, Symptom and Treatment Experiences Now 28 (LISTEN), collected data from adults with long COVID. The study sample included 423 29 participants enrolled between May 2022 and June 2023. 30 **Results:** The 423 participants had a median age of 46 years (interquartile range, 38-56), 74% 31 were female, 87% were Non-Hispanic White, and 158 (37%) reported "internal tremors, or 32 buzzing/vibration" as a long COVID symptom. Before long COVID, the groups had similar 33 comorbidities. Post-COVID, participants with internal tremors and vibrations had significantly 34 worse health as measured by the Euro-QoL visual analogue scale (median: 40 vs. 50 points, P =35 (0.007), higher rates of financial difficulties caused by the pandemic and housing insecurity (P < 36 0.001 for each), and were significantly more likely to have new-onset conditions of mast cell 37 disorders (11% vs. 2.6%), neurologic conditions (22% vs. 8.3%), anxiety (20% vs. 8.7%), and 38 trauma- or stress-related mental health disorders (12% vs. 3.4%) compared with those without 39 internal tremors (Bonferroni-adjusted P < 0.05 for each). Participants with internal tremors also 40 reported significantly higher rates of cardiovascular, gastrointestinal, integumentary, and 41 neurologic long COVID symptoms compared with those without internal tremors (Bonferroni-42 adjusted P < 0.05 for each).

3

# 43 Conclusions and Relevance: Among people with long COVID, those with internal tremors and

- 44 vibrations have more associated symptoms and worse health status, suggesting it may be
- 45 associated with a severe phenotype of the condition.

4

## 46 **INTRODUCTION**

47 Internal tremors and vibrations are an understudied symptom, despite their first written descriptions by a patient in the 1800s.<sup>1</sup> Internal tremors were described as a movement or 48 49 sensation of movement at any location inside the body. They can occur either with or without 50 visible external movement or muscle spasms.<sup>2, 3</sup> Until recently, internal tremors have been 51 described mostly among patients with Parkinson's disease and essential tremor.<sup>1-6</sup> In those 52 populations, internal tremors have been associated with anxiety and sensory abnormalities such 53 as aching, tingling, and burning.<sup>5</sup> In a recent qualitative study, we described long COVID 54 symptoms of internal tremors and vibrations and their substantial and negative impact on people's quality of life.<sup>2</sup> 55

56 Here, we compared the demographics, socioeconomic characteristics, pre-pandemic 57 comorbidities, and new-onset conditions between people with long COVID symptoms of internal 58 tremors and vibrations and others with long COVID. To the best of our knowledge, to date, no 59 quantitative study has described long COVID symptoms of internal tremors and vibrations. 60 Throughout this paper, terminology and definitions were deliberately chosen to respect 61 participants' epistemic authority. For example, long COVID was defined by participants' selfreport rather than definitions proposed by public health and medical organizations.<sup>7</sup> Similarly, 62 63 this paper used the term "internal tremors," a shortened phrase to denote "internal tremors and 64 vibrations," which reflects the language used by participants to describe their symptom 65 experience. Internal tremors were considered to be different from tremors, which were defined by expert consensus as "involuntary, rhythmic, oscillatory movement of a body part."<sup>8</sup> In this 66 67 paper's context, internal tremors were considered a participant-reported symptom rather than a 68 clinician-observed sign.<sup>9</sup>

5

#### 69

#### 70 METHODS

71 <u>Study design</u>

72 We used data from the long COVID component of the Listen to Immune, Symptom, and 73 Treatment Experiences Now (LISTEN) Study, an online, decentralized, participant-centric, 74 observational study of adults interested in contributing to COVID-related research. The LISTEN 75 Study included two parts: survey and electronic health record data collection and analysis to 76 characterize clinical phenotypes and biospecimen collection for immunophenotyping. This study 77 focused on survey data only. 78 Study sample 79 LISTEN recruited from people who joined Hugo Health Kindred, an online platform of

individuals 18 years and older who were interested in contributing to COVID-related research.
The objective was to include people with long COVID, vaccine-associated adverse events, and
those who could act as controls; this study focused on people with long COVID. People joined
Hugo Health Kindred by word of mouth, including via social media. Additionally, a subset of
active Kindred members was invited to join a Kindred Advisory Task Force to help recruit others
by sharing information about Kindred. Eligibility criteria to join LISTEN were 1) age 18 years or
older and 2) English speaking.

87 <u>Data collection</u>

88 Those who joined Kindred were offered a series of surveys developed in an iterative 89 process that included input from people with long COVID and those with vaccine-associated 90 adverse events. Surveys were available for completion online on computers or mobile devices. 91 Participants were sent electronic reminders to encourage survey completion. The data became

92	part of each person's data repository, available to be shared with research studies. People in
93	Kindred were offered the opportunity to join LISTEN; e-consent was performed online.
94	This study was restricted to people who joined LISTEN and had completed their
74	This study was restricted to people who joined Ers i Erv and had completed then
95	demographic and conditions and symptoms surveys. Participants with long COVID were
96	identified as those who replied "yes" to the question, "Do you think you have long COVID?"
97	Demographic and socioeconomic survey items included age, gender, race and ethnicity,
98	marital status, pre-pandemic employment and income, housing insecurity, and country of
99	residence. Self-reported time of index SARS-CoV-2 infection was categorized as Pre-Delta
100	(before 26 June 2021), Delta (26 June 2021–24 December 2021), Omicron (25 December 2021–
101	25 June 2022), and Post-Omicron (after 25 June 2022), consistent with time period definitions
102	associated with dominant variants of SARS-CoV-2.10 SARS-CoV-2 infection severity was
103	assessed by self-reported hospitalization history for COVID-related conditions.
104	The demographic survey included two questions about health status; self-reported health
105	status was assessed by the Euro-QoL visual analogue scale (EQ-VAS), and the question, "We are
106	trying to get a sense of how bad your long COVID symptoms are when you feel them the most.
107	On the slider below, with 0 being a trivial illness and 100 being unbearable, please let us know
108	what the worst days are like." (S1 Methods - Health status questions). <sup>11</sup>
109	The conditions and symptoms survey assessed pre-pandemic comorbidities, current
110	conditions, and long COVID symptoms. Pre-pandemic comorbidities were assessed using the
111	question, "Have you ever been told by a doctor before January 2020 that you have any of the
112	following?" followed by a list of 30 medical diagnostic categories, 8 psychiatric diagnostic
113	categories, "other," and "none of the above" (S2 Methods – Pre-pandemic comorbidities
114	questions). Current conditions were assessed using the question, "Currently, have you ever been

7

115	told by a doctor that you have any of the following?" followed by a list of 31 medical diagnostic
116	categories, 8 psychiatric diagnostic categories, "other," and "none of the above" (S2 Methods -
117	Current conditions questions). For each participant, we defined new-onset conditions as those
118	reported as a current condition but not reported as a pre-pandemic comorbidity.
119	Long COVID symptoms were assessed by the question, "Please select all following
120	health conditions that you have had as a result of long COVID," followed by a list of 95 specific
121	symptoms, "other," and "none of the above" (S3 Methods - Long COVID symptoms questions).
122	All phrasings of symptoms on the multiple-choice list were created in collaboration with
123	participants and were reported in this study's tables as they appeared on the survey. We excluded
124	the fatigue symptom and runny nose symptom variables from analysis due to their overlap with
125	the excessive fatigue symptom and congested or runny nose symptom.
126	After exclusion for incomplete conditions and symptoms surveys, the study sample
127	represented 69% of participants enrolled in LISTEN who completed the demographic survey and
128	reported long COVID and no vaccine-associated adverse events.
129	Statistical analysis
130	We described participant characteristics using percentages for categorical variables, and
131	median and interquartile range (IQR) for continuous variables. We compared participants with
132	and without internal tremors on their demographic and socioeconomic characteristics, medical
133	conditions, and long COVID symptoms. We used chi-squared tests and Fisher's exact tests to
134	compare responses for categorical variables and Wilcoxon rank-sum tests and Kruskal-Wallis
135	rank-sum tests for continuous variables. When comparing the three domains of pre-pandemic
136	comorbidities, new-onset conditions, and long COVID symptoms between the two groups, we

137 corrected for multiple testing using the Bonferroni method within each domain and reported

138	adjusted P-values. All tests were two-sided. $P < 0.05$ was considered statistically significant. By
139	using the Bonferroni method, family-wise error rates were controlled at the level of 0.05. All
140	statistical analyses were done in R version 4.2.3 (2023-03-15).
141	Ethical considerations
142	The LISTEN study was approved by the Yale University Institutional Review Board on
143	April 1, 2022. Participants were provided electronic written consent forms. LISTEN conforms to
144	the Declaration of Helsinki and STROBE reporting guidelines.
145	
146	RESULTS
147	From 7 May 2022 to 1 June 2023, 614 people with long COVID consented to and
148	enrolled in LISTEN and completed the demographic survey (Figure 1). Among them, 191
149	participants (31%) were excluded due to incomplete conditions and symptoms surveys, leaving
150	423 participants (69%) in the study population (Figure 1). The included participants were
151	significantly older (median: 46 years vs. 43 years, $P = 0.014$ ) compared with those who were
152	excluded from the analysis (S1 Table). The participants were similar in gender, race and
153	ethnicity, country of residence, and EQ-VAS health status.
154	Demographic and pre-pandemic socioeconomic characteristics
155	Among participants with long COVID, median age was 46 years (IQR, 38-56), 74% were
156	female, 87% were Non-Hispanic White, and 158 participants (37%) reported internal tremors
157	(Table 1). Compared with participants without internal tremors, those with internal tremors were
158	more likely to be female (81% vs. 70%, $P = 0.018$ ). The two groups had no significant
159	differences in age, race and ethnicity, marital status, pre-pandemic employment status, and pre-
160	pandemic household income ( $P > 0.05$ ).

## 9

## 161 <u>Pre-pandemic comorbidities</u>

162	Overall, among participants, the most common self-reported pre-pandemic comorbidities
163	were anxiety disorders (30%), depressive disorders (29%), and gastrointestinal issues, including
164	irritable bowel syndrome and acid reflux (24%). After adjusting for multiple testing, participants
165	with and without internal tremors were not significantly different in any self-reported pre-
166	pandemic comorbidities (adjusted $P > 0.05$ for each; S2 Table).
167	SARS-CoV-2 infection characteristics and post-COVID socioeconomic characteristics
168	Overall, the most common period for index SARS-CoV-2 infection was during the Pre-
169	Delta wave (46%) and 9.5% of participants were hospitalized due to COVID-related conditions
170	(Table 2, S1 Figure). Participants with internal tremors were significantly more likely to report
171	their index infection during the Pre-Delta wave (53% vs. 42%, $P = 0.006$ ) but were not
172	significantly different in hospitalization rates due to COVID-related conditions. Participants with
173	internal tremors had a significantly longer duration between their initial infections and the date of
174	completing LISTEN's symptom survey (median: 74 weeks vs. 54 weeks, $P = 0.003$ ).
175	Participants with and without internal tremors had no significant differences in their
176	health insurance status and level of social support when completing the surveys (P > 0.05; Table
177	2). Participants with internal tremors were significantly more likely to report having financial
178	difficulties caused by the pandemic (very much financial difficulties, 22% vs. 11%, $P < 0.001$ ),
179	often feeling socially isolated (43% vs. 37%, $P = 0.039$ ), and housing insecurity (worried about
180	losing housing, 18% vs. 8.3%, P < 0.001).
181	Health status

Participants with internal tremors reported significantly worse health as measured by EQVAS, using a visual sliding scale ranging from 0 to 100, where 0 means the worst and 100 means

184	the best (median: 40 points [IQR, 30-60] vs. 50 points [IQR, 35-62], P = 0.007) compared with
185	those with no internal tremors (Table 3, Figure 2). When asked to rate their symptom severity on
186	their worst days using a visual sliding scale ranging from 0 to 100, with 0 being a trivial illness
187	and 100 being unbearable, participants with internal tremors reported greater symptom severity
188	compared with those with no internal tremors (median: 80 points [IQR 73-90] vs. 73 points
189	[IQR, 60–82], respectively, $P < 0.001$ ; Table 3, Figure 3). In both groups, the time period of the
190	index SARS-CoV-2 infection was not significantly associated with EQ-VAS scores (S3 Table).
191	New-onset conditions
192	Overall, the most common new-onset conditions among all participants were postural
193	orthostatic tachycardia syndrome or other dysautonomia (25%), gastrointestinal issues (15%),
194	and neurologic conditions (13%) (S4 Table). Compared with participants without internal
195	tremors, significantly greater proportions of participants with internal tremors reported new-
196	onset mast cell disorders (11% vs. 2.6%, adjusted $P = 0.008$ ), neurologic conditions (22% vs.
197	8.3%, adjusted P = 0.004), anxiety disorders (20% vs. 8.7%, adjusted P = 0.038), and trauma-
198	and stressor-related disorders (12% vs. 3.4%, adjusted $P = 0.019$ ; Figure 2, S4 Table).
199	Long COVID symptoms
200	Overall, the most common long COVID symptoms reported were excessive fatigue
201	(87%), brain fog (86%), exercise intolerance (79%), trouble falling or staying asleep (72%), and
202	memory problems (70%) (S5 Table). Among participants with internal tremors, the most
203	common symptoms appeared to affect constitutional, neurological, and cardiovascular systems.
204	For constitutional and generalized symptoms, from most common to least common,
205	participants with internal tremors had significantly higher rates of trouble falling or staying
206	asleep (84% vs. 65%), dizziness (75% vs. 49%), muscle or body aches (70% vs. 49%), heat

11

207 intolerance (61% vs. 38%), night sweats (54% vs. 34%), chills but no fever (49% vs. 26%), 208 constant thirst (41% vs. 17%), feelings of impending doom (35% vs. 19%), nightmares (26% vs. 209 12%), abnormally low temperature (22% vs. 7.5%), and fainting (19% vs. 4.9%) compared with 210 those without internal tremors (adjusted P < 0.05 for each; S5 Table). Rates of exercise 211 intolerance and excessive fatigue did not differ significantly between the two groups (adjusted 212 P > 0.05 for each). 213 For neurological symptoms, from most common to least common, participants with 214 internal tremors were more likely to have headaches (77% vs. 56%), tingling, pins and needles, 215 or numbness (72% vs. 41%), tremors or shakiness (65% vs. 22%), neuropathy (nerve sensations 216 including pain) anywhere in the body (64% vs. 34%), pressure at the base of the head (51% vs. 217 27%), burning sensations (42% vs. 19%), migraines (42% vs. 23%), and painful scalp (25% vs. 218 8.7%) compared with those with no internal tremors (adjusted P < 0.05 for each; S5 Table). 219 Participants with internal tremors were also more likely to have auditory, visual, and olfactory symptoms such as tinnitus (62% vs. 36%), loss or decrease in quality of vision/blurry vision 220 221 (54% vs. 34%), floaters or flashes of light in vision (47% vs. 16%), changed sense of smell (42% 222 vs. 25%), and phantom smells (35% vs. 16%) compared with those without internal tremors 223 (adjusted P < 0.05 for each). The two groups were not significantly different in rates of 224 confusion, brain fog, memory problems, difficulty speaking, seizures, loss of hearing, and 225 gustatory symptoms (adjusted P > 0.05 for each). 226 For cardiovascular and thoracic symptoms, from most common to least common, 227 participants with internal tremors were more likely to have palpitations (66% vs. 44%), 228 tachycardia after standing up (58% vs. 39%) or at rest (57% vs. 34%), sharp or sudden chest pain 229 (47% vs. 22%), persistent chest pain or pressure (44% vs. 26%), costochondritis (37% vs. 18%),

230	and bilateral neck throbbing (23% vs. 7.5%) compared with those without internal tremors
231	(adjusted $P < 0.05$ for each; S5 Table). The two groups were not significantly different in rates of
232	pulmonary symptoms such as cough, wheezing, and shortness of breath (adjusted $P > 0.05$ for
233	each).
234	Participants with internal tremors were more likely to have integumentary symptoms
235	such as hair loss (56% vs. 30%), itchiness (39% vs. 17%), skin bruising (32% vs. 16%), change
236	in nails (30% vs. 13%), discoloration of the skin (29% vs. 11%), cracked or dry lips (28% vs.
237	13%), tender or itchy rash or chilblains on the toes or foot (15% vs. 1.9%), and chilblains on the
238	hands or feet (11% vs. 2.3%) compared with those with no internal tremors (adjusted $P < 0.05$
239	for each; S5 Table).
240	For gastrointestinal symptoms, participants with internal tremors were more likely to
241	have abdominal pain (47% vs. 23%), diarrhea (43% vs. 24%), loss of appetite (41% vs. 24%),
242	throat pain or discomfort (34% vs. 16%), inability to eat or tolerate food (32% vs. 15%),
243	difficulty swallowing (27% vs. 12%), and lump in throat (22% vs. 9.1%) compared with those
244	with no internal tremors (adjusted $P < 0.05$ for all; S5 Table). The two groups were not
245	significantly different in rates of other gastrointestinal symptoms such as acid reflux/heartburn,
246	constipation, and nausea/vomiting (adjusted $P > 0.05$ for each).
247	
248	DISCUSSION
249	In a cross-sectional sample of people with long COVID, we found internal tremors were
250	a common symptom, affecting 37% of participants. Participants with internal tremors were like
251	those without internal tremors in their demographic characteristics. Importantly, although the
252	two groups had similar pre-pandemic comorbidities, participants with internal tremors had worse

13

EQ-VAS health status and higher rates of financial difficulties caused by the pandemic and
housing insecurity compared with those without internal tremors. Participants with internal
tremors reported significantly higher rates of new-onset conditions for mast cell disorders,
neurologic disorders, anxiety disorders, and trauma- and stress-related disorders. Participants
with internal tremors also reported significantly higher rates of cardiovascular, neurologic,
gastrointestinal, and integumentary long COVID symptoms.

259 To the best of our knowledge, only four prior studies have described patients with internal tremors;<sup>3-5, 12</sup> no quantitative study of patients with long COVID has fully described 260 261 symptoms of internal tremors. A prior study of patients with Parkinson's disease found that 262 internal tremors were associated with anxiety and sensory symptoms such as aching, tingling, and burning.<sup>5</sup> Sensory abnormalities have also been described in long COVID cohorts,<sup>13</sup> as well 263 as in the subset of people with post-COVID onset of neuropathies<sup>14</sup>, such as small fiber 264 neuropathy.<sup>15, 16</sup> These prior long COVID studies described sensory symptoms such as burning, 265 tingling, and numbness, but did not explicitly describe internal tremors and vibrations. Two 266 267 recent studies based on large prospective cohorts of people with long COVID did not report on symptoms of internal tremors.<sup>10, 17</sup> Our study adds to prior findings by showing that compared 268 269 with others with long COVID, participants with internal tremors had significantly higher rates of 270 sensory abnormalities such as neuropathy sensations, olfactory changes, and tinnitus.

271 Prior studies also noted associations among dysautonomia, long COVID, and small fiber 272 neuropathy.<sup>16, 18</sup> Compared with participants with no internal tremors, those with internal tremors 273 reported significantly higher rates of symptoms across multiple autonomic domains, including 274 orthostatic symptoms (tachycardia, dizziness, fainting, and weakened neck, which may resemble 275 coat hanger syndrome<sup>19</sup>), vasomotor symptoms (skin discoloration), secretomotor (night sweats,

276	dry eyes), and symptoms related to slow or fast gastrointestinal transit (difficulty swallowing,
277	diarrhea). <sup>19-21</sup> Rates of new-onset dysautonomia were higher among participants with internal
278	tremors, with statistical significance before but not after Bonferroni correction. The mechanism
279	of dysautonomia among patients with Parkinson's disease may be related to organ-selective
280	sympathetic denervation, <sup>22</sup> but the pathophysiologic links among dysautonomia, long COVID,
281	and internal tremors have not been established and should be explored in further studies.
282	In this study, participants with internal tremors had new-onset mast cell disorders at a
283	significantly higher rate compared with participants with long COVID but no internal tremors.
284	Mast cells form neuroimmune synapses with peripheral nerves and serve both an afferent role to
285	modulate neural function, as well as an efferent role in neurogenic inflammation. <sup>23</sup> Mast cell
286	activation symptoms have been documented among long COVID patients <sup>24</sup> and patients with
287	small fiber neuropathy. <sup>25</sup> Further studies will be needed to elucidate the underlying
288	pathophysiologic link and determine if any subset of long COVID conditions and mast cell
289	disorders are causally related.
290	Our findings add nuance to the hypothesized associations between myalgic
291	encephalomyelitis/chronic fatigue syndrome and long COVID, which are often discussed
292	together due to overlapping symptomatology and infectious etiopathogenesis. <sup>26-28</sup> Although
293	greater than 70% of all subgroups in this study reported excessive fatigue and exercise
294	intolerance, these hallmark symptoms of myalgic encephalomyelitis/chronic fatigue syndrome
295	were not significantly associated with internal tremors. Our findings are consistent with prior
296	observations of long COVID as a heterogeneous condition with many phenotypes, <sup>29</sup> which may
297	be driven by several mechanisms. <sup>30</sup>
298	Study limitations

15

299	This study has several limitations. The study sample was recruited from an online long
300	COVID community and should not be considered representative. Rather, the study provides an
301	opportunity to describe the characteristics of people within the online community who do and do
302	not have internal tremors and vibrations. In this study, 31% of enrolled participants with long
303	COVID did not complete their conditions and symptoms surveys. The effort required to
304	complete surveys may preclude those with low functional status from participation. However,
305	participants included and excluded based on symptom survey completion were similar in their
306	low median EQ-VAS score. In addition, conditions and symptoms are based on self-reporting
307	using a pre-specified checklist, which may be susceptible to recall bias with unclear
308	directionality for under versus overreporting, as well as inaccuracies such as misdiagnoses due to
309	uncertainties surrounding long COVID evaluation and management during early stages of the
310	pandemic.
211	

311 <u>Conclusions</u>

312 Internal tremors and vibrations are common symptoms among people with long COVID. 313 People with these symptoms had pre-infection characteristics similar to those of others with long 314 COVID, but compared with others who had long COVID, they had worse EQ-VAS health status 315 and higher rates of financial difficulties and housing insecurity, and higher self-reported rates of 316 new-onset conditions of mast cell disorders, neurologic conditions, anxiety, and trauma- and stressor-related conditions. Individuals with long COVID symptoms of internal tremors may 317 318 experience a particularly severe phenotype of long COVID. Clinicians should be aware of 319 internal tremors and vibrations as a long COVID symptom. Further research is needed to clarify 320 the pathophysiology of internal tremors and vibrations and identify potential treatment targets.

16

## 321 ACKNOWLEDGMENTS

322 We thank Shaun Barcavage, FNP-BC, James Curry, MD, and Kelley Royer, RN for their

323 feedback and for sharing their lived experiences with the writing team, and Maria Johnson for

324 her editorial contributions.

325

#### 326 FUNDING

327 This study was in part funded by the Howard Hughes Medical Institute Collaborative COVID-19

328 Initiative, and grants from the National Institute of Allergy and Infectious Diseases

329 (R01AI157488 to Akiko Iwasaki).

330

#### 331 CONFLICTS OF INTEREST

Harlan Krumholz and his spouse are co-founders of, and have equity in, Hugo Health, the

333 personalized health data-platform company that developed the Hugo Kindred platform. Dr.

334 Krumholz is a scientific advisor to, and his spouse is an officer with, Hugo Health. His

involvement in this study is overseen by the Yale Conflict of Interest Committee. In the past

three years, Harlan Krumholz received expenses and/or personal fees from UnitedHealth,

337 Element Science, Eyedentifeye, and F-Prime. He is a co-founder of Refactor Health and is

associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare &

339 Medicaid Services and through Yale University from the Food and Drug Administration,

340 Johnson & Johnson, Google, and Pfizer.

## 17


#### 341 **REFERENCES**


- 342 Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW. An essay on Wilhelm von 1. 343 Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a 344 patient. Neurology. Mar 1995;45(3 Pt 1):565-8. doi:10.1212/wnl.45.3.565 345 Massey D, Baker AD, Berrent DZ, et al. Internal tremors and vibration symptoms among 2. 346 people with post-acute sequelae of SARS-CoV-2: a narrative review of patient reports. medRxiv. 347 2021:2021.12.03.21267146. doi:10.1101/2021.12.03.21267146 348 Cochrane GD, Rizvi S, Abrantes A, Crabtree B, Cahill J, Friedman JH. Internal tremor in 3. 349 Parkinson's disease, multiple sclerosis, and essential tremor. Parkinsonism Relat Disord. Oct 350 2015;21(10):1145-7. doi:10.1016/j.parkreldis.2015.07.014 351 Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand. Nov 4. 352 2001;104(5):312-5. doi:10.1034/j.1600-0404.2001.00357.x 353 Shulman LM, Singer C, Bean JA, Weiner WJ. Internal tremor in patients with 5. 354 Parkinson's disease. Mov Disord. Jan 1996;11(1):3-7. doi:10.1002/mds.870110103 355 Friedman JH. Non-motor movement disorders: internal tremor. Med Health R I. Aug 6. 356 2009;92(8):262. 357 Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition 7. 358 Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 359 condition by a Delphi consensus. Lancet Infect Dis. Apr 2022;22(4):e102-e107. 360 doi:10.1016/S1473-3099(21)00703-9 361 Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors. 8. 362 from the task force on tremor of the International Parkinson and Movement Disorder Society. 363 Mov Disord. Jan 2018;33(1):75-87. doi:10.1002/mds.27121 Louis ED, Bain PG. Problems and controversies in tremor classification. J Neurol Sci. 364 9. 365 Apr 15 2022;435:120204. doi:10.1016/j.jns.2022.120204 366 Gottlieb M, Wang R, Yu H, et al. Severe fatigue and persistent symptoms at three months 10. 367 following SARS-CoV-2 infections during the Pre-Delta, Delta, and Omicron time periods: a 368 multicenter prospective cohort study. Clin Infect Dis. Jan 27 2023;doi:10.1093/cid/ciad045 369 11. Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group. 370 Annals of Medicine. 2001/01/01 2001;33(5):337-343. doi:10.3109/07853890109002087 371 Borromei A, Caramelli R, Battistelli P, D'Orsi U, Pasini W, Vargiu B. 5-30-01 Internal 12. 372 tremor: a clinical marker for the onset of Parkinson's disease? Journal of the Neurological 373 Sciences. Sep 1997;150:S315. doi:10.1016/S0022-510X(97)86438-6 374 Writing Committee for the COMEBAC Study Group, Morin L, Savale L, et al. Four-13. 375 Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. Apr 376 20 2021;325(15):1525-1534. doi:10.1001/jama.2021.3331 377 Oaklander AL, Mills AJ, Kelley M, et al. Peripheral neuropathy evaluations of patients 14. 378 with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm. May 379 2022;9(3)doi:10.1212/NXI.00000000001146 380 Abrams RMC, Simpson DM, Navis A, Jette N, Zhou L, Shin SC. Small fiber neuropathy 15. 381 associated with SARS-CoV-2 infection. Muscle Nerve. Apr 2022;65(4):440-443. 382 doi:10.1002/mus.27458 383 Novak P, Giannetti MP, Weller E, et al. Network autonomic analysis of post-acute 16. 384 sequelae of COVID-19 and postural tachycardia syndrome. Neurol Sci. Dec 2022;43(12):6627-
- 385 6638. doi:10.1007/s10072-022-06423-y

18

- Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute
  Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023;329(22):1934-1946.
- 388 doi:10.1001/jama.2023.8823
- 389 18. Shoenfeld Y, Ryabkova VA, Scheibenbogen C, et al. Complex syndromes of chronic
- 390 pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber
- 391 neuropathy. Clin Immunol. May 2020;214:108384. doi:10.1016/j.clim.2020.108384
- 392 19. Goldstein DS, Cheshire WP, Jr. The autonomic medical history. *Clin Auton Res.* Aug
- 393 2017;27(4):223-233. doi:10.1007/s10286-017-0425-7
- 394 20. Kim MJ, Farrell J. Orthostatic hypotension: a practical approach. *Am Fam Physician*. Jan
  395 1 2022;105(1):39-49.
- 396 21. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and
- abbreviated Composite Autonomic Symptom Score. *Mayo Clin Proc.* Dec 2012;87(12):1196201. doi:10.1016/j.mayocp.2012.10.013
- 399 22. Goldstein DS. Dysautonomia in Parkinson disease. *Compr Physiol*. Apr 2014;4(2):805400 26. doi:10.1002/cphy.c130026
- 401 23. Forsythe P. Mast cells in neuroimmune interactions. *Trends Neurosci.* Jan 2019;42(1):43402 55. doi:10.1016/j.tins.2018.09.006
- 403 24. Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell
- 404 activation symptoms are prevalent in Long-COVID. *Int J Infect Dis.* Nov 2021;112:217-226.
  405 doi:10.1016/j.ijid.2021.09.043
- 406 25. Novak P, Giannetti MP, Weller E, Hamilton MJ, Castells M. Mast cell disorders are
- 407 associated with decreased cerebral blood flow and small fiber neuropathy. *Ann Allergy Asthma*408 *Immunol.* Mar 2022;128(3):299-306 e1. doi:10.1016/j.anai.2021.10.006
- 409 26. Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue
- 410 syndrome (ME/CFS)-a Systemic review and comparison of clinical presentation and
- 411 symptomatology. *Medicina (Kaunas)*. Apr 26 2021;57(5)doi:10.3390/medicina57050418
- 412 27. Retornaz F, Rebaudet S, Stavris C, Jammes Y. Long-term neuromuscular consequences
- 413 of SARS-Cov-2 and their similarities with myalgic encephalomyelitis/chronic fatigue syndrome:
- results of the retrospective CoLGEM study. *J Transl Med.* Sep 24 2022;20(1):429.
- 415 doi:10.1186/s12967-022-03638-7
- 416 28. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes.
  417 *Nat Med.* May 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6
- 418 29. Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2
- 419 infection subphenotypes. Nat Med. Jan 2023;29(1):226-235. doi:10.1038/s41591-022-02116-3
- 420 30. Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long
- 421 COVID: a comprehensive review. *Ann Med.* Dec 2022;54(1):1473-1487.
- 422 doi:10.1080/07853890.2022.2076901
- 423

#### 425 TABLES AND FIGURES






#### 431 Figure 2. Distribution of health status, measured by the Euro-QoL visual analogue scale




Assessed by the question, "Please choose one point in this 0-100 scale, which can best represent your health today (0 means the worst and 100 means the best)." (S1 Methods - Health status

0 means the worst and 100 means the best

- 434
- 435 questions)
- 436






438

Assessed by the question, "We are trying to get a sense of how bad your long COVID symptoms
are when you feel them the most. On the slider below, with 0 being a trivial illness and 100 being
unbearable, please let us know what the worst days are like." (S1 Methods - Health status

- 442 questions)
- 443



### 445 Figure 4. New-onset conditions

446 447

- 448 \* Bonferroni adjusted p < 0.05
- 449 \*\* Bonferroni adjusted p < 0.01

- 451 Abbreviations: MCAS, mast cell activation syndrome; ME/CFS, myalgic
- 452 encephalomyelitis/chronic fatigue syndrome; POTS, postural orthostatic tachycardia syndrome

453

	<b>Overall</b> , N = 423	No internal tremors, N = 265	Has internal tremors, N = 158	p- value
	n/N, % [95% CI]	n/N, % [95% CI]	n/N, % [95% CI]	
Age (years), median, IQR	46, 38-56	46, 39-58	46, 38-53	0.225
Gender				0.018
Female	313/423, 74% [69-78%]	185/265, 70% [64- 75%]	128/158, 81% [74- 87%]	
Male	108/423, 26% [21-30%]	78/265, 29% [24- 35%]	30/158, 19% [13- 26%]	
Non-binary	2/423, 0.5% [0.08-1.9%]	2/265, 0.8% [0.13- 3.0%]	0/158, 0% [0.00- 3.0%]	
Race and ethnicity				0.458
Asian	11/423, 2.6% [1.4-4.7%]	9/265, 3.4% [1.7- 6.6%]	2/158, 1.3% [0.22- 5.0%]	
Black	8/423, 1.9% [0.88-3.8%]	6/265, 2.3% [0.92- 5.1%]	2/158, 1.3% [0.22- 5.0%]	
Latino	15/423, 3.5% [2.1-5.9%]	7/265, 2.6% [1.2- 5.6%]	8/158, 5.1% [2.4- 10%]	
Multiracial or Other	21/423, 5.0% [3.2-7.6%]	13/265, 4.9% [2.7- 8.4%]	8/158, 5.1% [2.4- 10%]	
Non-Hispanic White	368/423, 87% [83-90%]	230/265, 87% [82- 91%]	138/158, 87% [81- 92%]	
Country of residence				0.807
Canada	11/423, 2.6% [1.4-4.7%]	7/265, 2.6% [1.2- 5.6%]	4/158, 2.5% [0.81- 6.8%]	
Germany	5/423, 1.2% [0.44-2.9%]	2/265, 0.8% [0.13- 3.0%]	3/158, 1.9% [0.49- 5.9%]	
United Kingdom	5/423, 1.2% [0.44-2.9%]	3/265, 1.1% [0.29- 3.5%]	2/158, 1.3% [0.22- 5.0%]	

	I		1	1
U.S.	391/423, 92% [89-95%]	247/265, 93% [89- 96%]	144/158, 91% [85- 95%]	
Other countries	11/423, 2.6% [1.4-4.7%]	6/265, 2.3% [0.92- 5.1%]	5/158, 3.2% [1.2- 7.6%]	
Marital status				0.956
Divorced	42/398, 11% [7.8-14%]	27/253, 11% [7.3- 15%]	15/145, 10% [6.1- 17%]	
Married or civil union	237/398, 60% [55-64%]	151/253, 60% [53- 66%]	86/145, 59% [51- 67%]	
Never married	109/398, 27% [23-32%]	69/253, 27% [22- 33%]	40/145, 28% [21- 36%]	
Separated	6/398, 1.5% [0.61-3.4%]	3/253, 1.2% [0.31- 3.7%]	3/145, 2.1% [0.54- 6.4%]	
Widowed	4/398, 1.0% [0.32-2.7%]	3/253, 1.2% [0.31- 3.7%]	1/145, 0.7% [0.04- 4.4%]	
Missing data	25	12	13	
Employed pre-pandemic	338/396, 85% [81-89%]	213/252, 85% [79- 89%]	125/144, 87% [80- 92%]	0.537
Missing data	27	13	14	
Pre-pandemic annual household income				0.677
\$10,000 to \$35,000	20/396, 5.1% [3.2-7.8%]	12/252, 4.8% [2.6- 8.4%]	8/144, 5.6% [2.6- 11%]	
\$35,000 to less than \$50,000	29/396, 7.3% [5.0-10%]	15/252, 6.0% [3.5- 9.8%]	14/144, 9.7% [5.6- 16%]	
\$50,000 to less than \$75,000	38/396, 9.6% [7.0-13%]	25/252, 9.9% [6.6- 14%]	13/144, 9.0% [5.1- 15%]	
\$75,000 or more	274/396, 69% [64-74%]	176/252, 70% [64- 75%]	98/144, 68% [60- 75%]	
Less than \$10,000	4/396, 1.0% [0.32-2.7%]	2/252, 0.8% [0.14- 3.1%]	2/144, 1.4% [0.24- 5.4%]	

25

Prefer not to answer	31/396, 7.8% [5.5-11%]	22/252, 8.7% [5.7- 13%]	9/144, 6.2% [3.1- 12%]		
Missing data	27	13	14		
<sup>1</sup> Wilcoxon rank sum test; Fisher's exact test; Pearson's Chi-squared test					

26

# 455 Table 2. SARS-CoV-2 infection and post-COVID socioeconomic characteristics

456

	Overall, N = 423 n/N, % [95% CI]	No internal tremors, N = 265 n/N, % [95% CI]	Has internal tremors, N = 158 n/N, % [95% CI]	p- value <sup>1</sup>
Index SARS-CoV-2 infection time period				0.006
Pre-Delta	171/373, 46% [41-51%]	97/233, 42% [35-48%]	74/140, 53% [44-61%]	
Delta	48/373, 13% [9.7-17%]	27/233, 12% [7.9-17%]	21/140, 15% [9.7-22%]	
Omicron	110/373, 29% [25-34%]	72/233, 31% [25-37%]	38/140, 27% [20-35%]	
Post-Omicron	44/373, 12% [8.8-16%]	37/233, 16% [12-21%]	7/140, 5.0% [2.2-10%]	
Missing data	50	32	18	
Hospitalized for COVID-related conditions	40/423, 9.5% [6.9-13%]	20/265, 7.5% [4.8-12%]	20/158, 13% [8.1-19%]	0.082
Number of weeks between infection and taking the symptom survey	63, 32-111	54, 26-99 [59- 71]	74, 38-118 [71- 86]	0.003
Missing data	50	32	18	
Financial difficulties caused by the pandemic				< 0.001
Not at all	125/396, 32% [27-36%]	94/252, 37% [31-44%]	31/144, 22% [15-29%]	
A little	146/396, 37% [32-42%]	95/252, 38% [32-44%]	51/144, 35% [28-44%]	
Quite a bit	66/396, 17% [13-21%]	36/252, 14% [10-19%]	30/144, 21% [15-29%]	

Very much	59/396, 15% [12-19%]	27/252, 11% [7.3-15%]	32/144, 22% [16-30%]	
Missing data	27	13	14	
Do not have health insurance	15/423, 3.5% [2.1-5.9%]	9/265, 3.4% [1.7-6.6%]	6/158, 3.8% [1.6-8.5%]	0.829
Social support (someone around to help you if you need it)				0.766
Never	24/398, 6.0% [4.0-9.0%]	16/253, 6.3% [3.8-10%]	8/145, 5.5% [2.6-11%]	
Rarely	31/398, 7.8% [5.4-11%]	22/253, 8.7% [5.7-13%]	9/145, 6.2% [3.1-12%]	
Sometimes	72/398, 18% [15-22%]	42/253, 17% [12-22%]	30/145, 21% [15-28%]	
Usually	148/398, 37% [32-42%]	93/253, 37% [31-43%]	55/145, 38% [30-46%]	
Always	123/398, 31% [26-36%]	80/253, 32% [26-38%]	43/145, 30% [23-38%]	
Missing data	25	12	13	
Social isolation (how often do you feel isolated from others?)				0.039
Hardly ever or never	85/395, 22% [18-26%]	64/251, 25% [20-31%]	21/144, 15% [9.5-22%]	
Some of the time	155/395, 39% [34-44%]	94/251, 37% [32-44%]	61/144, 42% [34-51%]	
Often	155/395, 39% [34-44%]	93/251, 37% [31-43%]	62/144, 43% [35-52%]	
Missing data	28	14	14	
Housing				< 0.001
I do not have a steady place to live	4/398, 1.0% [0.32-2.7%]	0/253, 0% [0.00-1.9%]	4/145, 2.8% [0.89-7.4%]	

28

I have a place to live today, but I am worried about losing it in the future	47/398, 12% [8.9-15%]	21/253, 8.3% [5.3-13%]	26/145, 18% [12-25%]
I have a steady place to live	347/398, 87% [83-90%]	232/253, 92% [87-95%]	115/145, 79% [72-85%]
Missing data	25	12	13
<sup>1</sup> Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test			

29

# 459 <u>Table 3</u>. Health status

Characteristic	<b>Overall</b> , N = 423	No internal tremors, N = 265	Has internal tremors, N = 158	p- value <sup>1</sup>
	median, IQR	median, IQR	median, IQR	
Euro-QoL visual analogue scale (0- 100)	49, 32-61	50, 35-62	40, 30-60	0.007
How bad your long COVID or other symptoms are (0 to 100) on your worst days?	79, 65-86	73, 60-82	80, 73-90	< 0.001
Missing data	24	11	13	
<sup>1</sup> Wilcoxon rank sum test				
IQR, interquartile range				